Is Viatris Stock Outperforming the S&P 500? Viatris has comfortably outperformed the broader S&P 500 over the past year, with analysts maintaining a fairly bullish outlook on the stock. Barchart · Sep 24
Nightly Eye Drop Tested for Night Driving Glare Improved Dim-Light Vision in One in Five Adults in Trial A nightly phentolamine eye drop helped 21% of adults see better in dim light in a phase 3 trial. It is not approved for night-driving glare. Medical Daily · Sep 12
Is Wall Street Bullish or Bearish on Viatris Stock? Though Viatris has outpaced the broader market over the past year, Wall Street analysts maintain a cautiously optimistic outlook on the stock’s prospects. Barchart · Aug 4
FDA Approves Gwyn Lo, a Once Weekly Contraceptive Patch with a Lower Estrogen Dose FDA-approved Gwyn Lo is a weekly contraceptive patch with lower estrogen. It is limited to women with a BMI under 30 kg/m2. Medical Daily · Jul 31
Viatris’ Quarterly Earnings Preview: What You Need to Know Viatris is scheduled to report its second-quarter results next month, with Wall Street expecting earnings per share to remain roughly unchanged from a year ago. Barchart · Jul 22
Biocon shares jump 6% as Mylan likely exits drugmaker after Rs 3,481 crore stake sale Biocon shares experienced a significant jump of over 6% on Tuesday. Viatris-owned Mylan intends to sell a substantial stake, exiting the Indian drugmaker. This stake sale represents 5.64% of Biocon's outstanding shares. The offer's floor price was set at a discount to the previous closing price. Block deals totaling nearly… The Economic Times · Jul 14
How Is Viatris’ Stock Performance Compared to Other Healthcare Stocks? Viatris has outperformed its industry peers over the past year, and Wall Street appears optimistic about the stock. Barchart · Jun 19
Are Wall Street Analysts Bullish on Viatris Stock? Despite outperforming the broader market over the past year, Viatris continues to earn a cautiously optimistic outlook from Wall Street. Barchart · May 6
Viatris' Q1 2026 Earnings: What to Expect Viatris is set to announce its first-quarter earnings next month, and Wall Street expects the company’s EPS to increase by a single digit. Barchart · Apr 23
Anxiety drug Xanax is under recall. Here’s what to know The recalled pills may not break down in the body and release the drug at the right speed The Independent UK · Apr 15
Viatris Stock: Is VTRS Outperforming the Health Care Sector? As Viatris has outperformed the broader health care sector over the past year, and analysts remain moderately optimistic about the stock’s prospects. Barchart · Mar 23
What Are Wall Street Analysts' Target Price for Viatris Stock? Though Viatris has outpaced the broader market over the past year, Wall Street analysts maintain a cautiously optimistic outlook on the stock’s prospects. Barchart · Feb 2
Viatris Earnings Preview: What to Expect Viatris is set to report its fourth-quarter earnings soon, with analysts forecasting a slight decline in profits. Barchart · Jan 22
Barchart · Dec 15, 2025 Is Viatris Stock Outperforming the Dow? As Viatris has outperformed the Dow recently, analysts remain moderately optimistic about the stock’s prospects.
Barchart · Nov 4, 2025 Viatris Stock: Is Wall Street Bullish or Bearish? Viatris has underperformed the broader market in recent months, and analysts’ outlook remains guarded as the company executes on its transformation efforts.
Barchart · Sep 26, 2025 Is Viatris Stock Underperforming the Nasdaq? Viatris has lagged the broader Nasdaq Composite over the past year, and Wall Street sentiment toward the stock remains guarded.
Barchart · Aug 5, 2025 Viatris Stock: Analyst Estimates & Ratings Viatris has considerably underperformed the broader market over the past year, and analysts are cautious about the stock’s prospects.
Barchart · Jul 23, 2025 What to Expect From Viatris' Next Quarterly Earnings Report Viatris is all set to release its fiscal second-quarter earnings next month, and analysts project a double-digit earnings drop.
Benzinga · Jul 18, 2025 Viatris Hits Snag In Eye Drug Study—Phase 3 Plans Under Review As the pharmaceutical industry increasingly focuses on developing targeted treatments for niche conditions, Viatris Inc. (NASDAQ:VTRS) on Friday announced topline data from a Phase 3 study evaluating the efficacy and safety of pimecrolimus 0.3% (MR-139) ophthalmic ointment in subjects with blepharitis.
Barchart · Jun 24, 2025 Is Viatris Stock Underperforming the S&P 500? Viatris has significantly underperformed the S&P 500 over the past year, and analysts remain cautious about the stock’s prospects.
Barchart · May 7, 2025 Do Wall Street Analysts Like Viatris Stock? Viatris has underperformed the broader market over the past year, and analysts remain skeptical of the stock’s future potential.
Barchart · Apr 28, 2025 What to Expect From Viatris' Q1 2025 Earnings Report Viatris is scheduled to report its first-quarter results next month, and analysts expect a double-digit earnings drop.
Barchart · Apr 1, 2025 How Is Viatris’ Stock Performance Compared to Other Biotech Stocks? Over the past six months, Viatris has lagged behind its biotech peers, and Wall Street analysts continue to exercise caution regarding the stock's future outlook.
Barchart · Feb 5, 2025 Viatris Stock Outlook: Is Wall Street Bullish or Bearish? As Viatris has trailed the broader market over the past year, analysts are skeptical about its future outlook.